Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 combinations in 1L r/mTNBC
NCT06786026Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Oct 2024; status: recruiting.
02
Drugs
QL1706
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06786026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786026.